drugset
drugset / Trial / NCT03765983

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

NCT03765983 ↗

Phase 2 Terminated 17 enrolled Dana-Farber Cancer Institute Kazia Therapeutics Limited · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: * GDC-0084 * Trastuzumab (Herceptin®)

Timeline

Start
2019-02-25
Primary completion
2024-04-29
Completion
2024-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Paxalisib Small molecule 45 mg Oral
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous

Indications

breast cancer